Artificial Intelligence (AI) is revolutionizing various sectors, and biotech is no exception. AI’s ability to analyze vast amounts of data quickly and accurately is helping to accelerate drug discovery, improve clinical trials, and advance...

The U.S. Food and Drug Administration has recently approved the first gene-editing treatment, Casgevy, for sickle cell disease. This one-time treatment, developed by Vertex Pharmaceuticals (NASDAQ: VERX) and CRISPR Therapeutics (NASDAQ: CRSP), utilizes the...

During times of economic uncertainty and recession, many investors turn to defensive stocks that can provide stability amidst market volatility. However, growth stocks in industries resilient to downturns can also present lucrative opportunities. Here...

NVIDIA (NASDAQ: NVDA) Earnings NVIDIA is set to report earnings on November 21, 2023 for Q3 2024. Analysts estimate EPS of $0.58, down from $1.17 in Q3 2023. Revenue growth is expected to slow...